Aflibercept in Polypoidal Choroidal Vasculopathy

• Status: Completed
• Trial end date: 2017-07-07

Summary

To collect data reflecting the efficacy and safety of aflibercept with and without photodynamic therapy in subjects diagnosed with the polypoidal choroidal vasculopathy subtype of wet age-related macular degeneration

• Phase: Phase 4

Details

• Lead Sponsor: Bayer
• Collaborator: Regeneron Pharmaceuticals
• Treatments: Aflibercept; Verteporfin